Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. A great majority of GISTs is driven by pathological activation of KIT or platelet-derived growth factor receptor-a (PDGFRA), two closely related receptor tyrosine kinases. However, other genetic changes including gain-of-function BRAF mutations and loss of succinate dehydrogenase (SDH) complex activity have been identified in the subsets of KIT-, PDGFRA-wild type tumors. Genetic mutations affecting KIT, PDGFRA, BRAF and SDH complex functions are believed to be mutually exclusive events. Recently, KRAS codon 12 and 13 mutations were reported in a small subset of KIT or PDGFRA mutant GISTs. Moreover, in in vitro experiments, KIT mutants with concurrent KRAS mutation showed resistance to imatinib, a receptor tyrosine kinase inhibitor used in GIST treatment. The aim of this study was to evaluate a large cohort of GISTs to define frequency and clinical significance of KRAS mutations in this type of cancer. A well-characterized cohort of 514 GISTs was screened for KRAS mutations using Sanger sequencing (n ¼ 450) and pyrosequencing (n ¼ 64). In all, 350 gastric, 100 intestinal and 64 primary disseminated GISTs were analyzed. No KRAS mutations were found. In GIST, KRAS mutations are extremely rare if they exist (o0.2%). Thus, mutational activation of KRAS does not seem to play any significant role in the development and progression of this type of cancer. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. A great majority of GISTs is driven by pathological activation of KIT or platelet-derived growth factor receptor-a (PDGFRA), two closely related receptor tyrosine kinases. It has been shown that KIT and PDGFRA mutations are mutually exclusive genetic events. A small subset of GISTs lack KIT or PDGFRA mutations and are often referred to as KIT-and PDGFRA-wild-type (WT) GISTs. Recent studies revealed that WT GISTs represent a heterogeneous group of tumors, and classification into several subtypes including succinate dehydrogenase (SDH)-deficient GISTs, neurofibromatosis 1 (NF1)-associated GISTs and BRAF-mutant GISTs. 1 KIT and PDGFRA tyrosine kinase inhibitor, imatinib mesylate (STI571, commercially known as Gleevc/Glivec; http://www.novartis.com) has been successfully used to treat surgically inoperable primary and disseminated GISTs. Tumor sensitivity to imatinib differs among the patients and to some extent depends on GIST genotype. 2 Recently, KIT and PDGFRA mutants with concurrent KRAS mutations were reported. Based on in vitro experiments, it was concluded that presence of KRAS mutation can predict tumor resistance to imatinib treatment. 3 Thus, identification of such mutations might have clinical significance. A treatment employing other alternative tyrosine kinase inhibitors could be considered in such cases. 4 The aim of this study was to evaluate a large cohort of well-characterized GISTs to define frequency and clinical significance of KRAS mutations in this type of cancer. 
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Materials and methods
In all, 514 GISTs were selected for this study. All tumors were previously well characterized including immunohistochemical evaluation for DOG-1and KIT expression and mutation status of KIT and PDGFRA. 1 Control cohort consisted of 10 randomly selected colon carcinomas, expected to contain a high percentage of KRAS mutations.
The formalin-fixed paraffin-embedded (FFPE) tumor samples were selected for DNA extraction. Five to ten 5-mm thick sections were deparaffinized with xylene, washed twice in ethanol, lyophilized and incubated with 10 mg/ml proteinase K (Roche Diagnostics, Indianapolis, IN) in Hirt-Buffer at 55 1C for 24 h. Subsequently, DNA was recovered using Maxwell16 robotic system and DNA IQ case work pro kit (Promega, Madison, WI).
Sanger Sequencing
KRAS codons 12 and 13, and flanking sequences were PCR amplified with forward: 5 0 -GTGTGACATG TTCTAATATAGTCA-3 0 and reverse: 5 0 -AGAATGGT CCTGCACCAGTAATAT-3 0 primers. PCR amplifications were performed with AmpliTaq Gold DNA polymerase (Applied Biosystems, Roche, Branchburg, NJ) following standard three-temperature PCR protocol with denaturing at 94 1C, annealing at 45 1C and extension at 72 1C. 50 ml PCR reactions were evaluated on agarose gels. The 212-bp PCR products were extracted using QIAquick gel extraction kit (www.qiagen.com) and submitted for sequencing with above primers. Sanger direct sequencing was performed by MacrogenUSA (Rockville, MD). Obtained sequences were analyzed and aligned with KRAS reference sequence, NG_007524.1 (www.ncbi. nlm.nih.gov).
Pyrosequencing KRAS codons 12, 13 and 61 were evaluated by pyrosequencing using a PyroMark Q24 instrument and the PyroMark Q24 KRAS v2.0 kit (Qiagen, Valencia, CA). PCR reactions were conducted in a total volume of 25 ml containing genomic DNA template, 200 nM of each forward and reverse primers, and 12.5 ml 2x HotStarTaq Master Mix (Qiagen). COLD-PCR was used to enrich mutant alleles, which allows us to achieve a sensitivity to detect 2-3% mutant tumor cells. 5 
Results
In all, 514 GISTs including 350 gastric, 100 intestinal and 64 primary disseminated tumors were analyzed in this study. In all the cases, the diagnosis was confirmed by distinctive histology, KIT and/or DOG-1 expression and typical genotype. 1 There were 255 KIT mutants, 105 PDGFRA mutants and 117 KIT/ PDGFRA-WT GISTs. In 37 cases molecular genetic data were incomplete and 16 gastric KIT/PDGFRA-WT GISTs were confirmed to represent SDH-deficient tumors. 6 One small intestinal tumor was associated with NF1. Overall, 450 primary GISTs were screened for mutations using Sanger sequencing, the method used in the study, which reported presence of concurrent KRAS mutations in GISTs. 3 In search for KRAS mutations acquired during tumor progression, 64 metastatic tumors were evaluated using highly sensitive pyrosequencing.
No mutations were found in KRAS codons 12 and 13 using standard PCR amplification and Sanger direct sequencing of PCR products. Also, pyrosequencing failed to detect KRAS mutations in codons 12, 13 or 61 in 64 highly malignant, primary disseminated GISTs. Based on these results, we have concluded that the frequency of KRAS mutants in GISTs is o0.2%. In contrast, KRAS mutations were found by both Sanger direct sequencing and pyrosequencing in 6 of 10 colon carcinomas independently evaluated by Sanger sequencing and pyrosequencing.
Discussion
KRAS, a cellular homolog of the Kirsten rat sarcoma virus oncogene, is a member of RAS family that includes HRAS, KRAS and NRAS. 7, 8 RAS genes encode closely related, 21-kDa membrane-bound, intracellular proteins. These proteins relay mitogenic growth signals into cytoplasm and nucleus, and possess intrinsic GTPase activity. Gainof-function mutations in RAS diminished normal GTPase function and caused alterations of RAS-RAF-MAPK signaling pathway leading to increased cell proliferation. 9 In general, mutations affecting different components of this pathway were believed to represent mutually exclusive genetic events. 10 However, a few exceptions have been reported in the literature recently. 11 Gain-of-function KRAS mutations have been identified in different types of cancers, most commonly in colonic, pancreatic and pulmonary carcinomas and rarely in sarcomas. 12 A few studies reported KRAS mutations in GI leiomyosarcomas. 13, 14 However, incomplete immunohistochemical and molecular genetic data of these tumors cast some doubt on these results. 1 Also, previous studies have failed to detect KRAS mutations in GISTs, although they were based on relatively small number of cases. [15] [16] [17] [18] More recently, concurrent KRAS mutations were reported in KIT-or PDGFRA-mutant GISTs. 3 The study consisted of two GIST cohorts tested independently in Locarno, Switzerland and in Milan, Italy by standard PCR amplification and Sanger direct sequencing of PCR products. In the cohort from Locarno, 3 KRAS mutants (two gastric and one intestinal GIST) were identified among 60 analyzed tumors. Subsequent in vitro experiments showed that KRAS mutation can cause resistance of KIT-mutant GISTs to imatinib; 3 however, the clinical significance of this observation hinges on a reasonable frequency of such mutations.
Thus, in this study, a large cohort of wellcharacterized primary GISTs was evaluated for KRAS mutations using similar mutation-screening strategy. Based on frequency of KRAS mutations reported in the GIST cohort from Locarno, we expected to identify at least 20 mutants among our cases; however, no KRAS mutations were found. In contrast, KRAS codon 12 and 13 mutants were identified in 6 of the 10 colon carcinomas used as a control cohort, in which about 50% cases were expected to have KRAS mutation.
Studies of colorectal metastatic carcinomas have shown that KRAS mutations could be acquired during tumor progression. 19 No KRAS mutations have been yet reported in advanced or metastatic GISTs, although only a few such tumors were evaluated. Nevertheless mutational activation of PIK3CA, which is involved in KIT signaling pathway, was demonstrated in KIT/PDGFRA-WT, BRAF-mutant GIST at the time of progressive disease. 20 Considering the latter observation, we have decided to evaluate the hypothesis that KRAS mutations could be seen in GIST during tumor progression. Sixty-four metastatic GISTs were screened for KRAS mutations using COLD-PCR and pyrosequencing, a methodology of higher analytical sensitivity than Sanger sequencing; 21 however, no KRAS mutations were found.
A major difference in frequency of KRAS mutants between our and recently published study 3 is difficult to explain. Further investigations are necessary to confirm that some GISTs might have unique KRAS genotype as reported by the group from Ticino, Switzerland, although based on current (n ¼ 514) and previous studies (n ¼ 254) it seems that such mutants are extremely rare (Table 1) .
Proper characterization of genetic alteration in human cancers and reproducibility of research findings is essential for the design and improvement of preclinical and clinical cancer studies. 22 In arriving era of next generation sequencing, mutational profiling of GIST will be based on simultaneous evaluation of many genes from various signaling pathways. This strategy might lead to significant accumulation of data on mutational activation of various genes involved in KIT-signaling pathway including KRAS and validate studies based on Sanger sequencing. 
